ILF3 and hepatocellular carcinoma: In summary, our findings have unveiled the critical role of the ILF3‐MRPL12 axis in the development of targeted therapy resistance in HCC, and uncovered a previously unrecognized role of an antibiotic, lefamulin, in reversing drug resistance.